# Cancer Detection Research Task List

- [x] Create Implementation Plan <!-- id: 0 -->
- [x] Research HRD score calculation methodologies (Panel, WES, WGS) <!-- id: 1 -->
    - [x] Identify calculation methods for each platform
    - [x] Determine limitations for each platform
    - [x] Find standard cutoffs for HRD positive/negative
- [x] Research CMS/Reimbursement metrics for CGP <!-- id: 2 -->
    - [x] Identify Analytical Validity metrics
    - [x] Identify Clinical Validity metrics
    - [x] Identify Clinical Utility requirements
    - [x] Identify Clinical Utility requirements
    - [x] Determine data acquisition methods and timelines
    - [x] Research Clinical Utility strategies of Foundation, Guardant, Caris (PMA, NCD 90.2)
- [x] Refine Report 2: CGP Reimbursement Metrics <!-- id: 8 -->
    - [x] Explain PPA (Sensitivity) & NPA (Specificity) formulas (Numerator/Denominator)
    - [x] Explain LoD determination via Serial Dilution
    - [x] Convert Report 2 to DOCX
- [x] Research Genomic Drug Prescription without CDx <!-- id: 3 -->
    - [x] Investigate LDT CGP usage
    - [x] Investigate PCR requirements
    - [x] Identify safety protocols and prescription pathways
- [x] Generate Report 1: HRD Score Methodologies <!-- id: 4 -->
- [x] Generate Report 2: CGP Reimbursement Metrics <!-- id: 5 -->
- [x] Generate Report 3: Genomic Drug Prescription Pathways <!-- id: 6 -->
- [x] Analyze OncoKB Actionable Genes <!-- id: 9 -->
    - [x] Load and inspect CSV data
    - [x] Calculate CDx vs No-CDx counts for Level 1 (FDA)
    - [x] Identify Cancer Types with highest/lowest CDx coverage
    - [x] Identify Drugs/Indications lacking CDx
    - [x] Generate Report 4: OncoKB CDx Analysis
- [x] Analyze CDx Company Landscape <!-- id: 10 -->
    - [x] Map Companies to Devices and Indications
    - [x] Generate Report 5: CDx Company Landscape
- [x] Develop WGS CDx Strategy <!-- id: 11 -->
    - [x] Synthesize "No-CDx" gaps with WGS strengths
    - [x] Analyze TMB as a strategic opportunity
    - [x] Generate Report 6: Strategic Opportunities for WGS CDx
- [x] Explore Advanced WGS Opportunities <!-- id: 12 -->
    - [x] Research HLA LOH, Viral Integration, & PGx
    - [x] Update Report 6 with Advanced Strategies
    - [x] Generate Report 7: Deep Dive on Immuno-Gram & Safety Net
- [x] Quantify TMB Unmet Need <!-- id: 13 -->
    - [x] Research TMB-High non-response rates (ORR data)
    - [x] Update Report 7 with Unmet Need data
- [x] Quantify TMB False Positive Rate <!-- id: 14 -->
    - [x] Research concordance of Panel vs WGS TMB (Misclassification %)
    - [x] Update Report 7 with Technical Error data
- [x] Evaluate WES as TMB Ground Truth <!-- id: 15 -->
    - [x] Research WES vs WGS reliability for TMB
    - [x] Update Report 7 with WES specific nuances
- [x] Analyze MSI as a strategic opportunity <!-- id: 16 -->
    - [x] Research WGS vs PCR (Promega) sensitivity in Non-CRC
    - [x] Update Report 7 with "Universal MSI" strategy
- [x] Quantify Market Size (Prevalence) <!-- id: 17 -->
    - [x] Research US annual incidence for Heme/Solid targets
    - [x] Research biomarker frequency (NTRK%, TMB-H%, MSI-H%)
    - [x] Update Report 6 Summary with Market Size
- [x] Develop WGS Market Winning Strategy <!-- id: 18 -->
    - [x] Synthesize "3-Pillar" Strategy (Differentiation, Consolidation, Safety)
    - [x] Result: Verified WES correlation (0.98) but confirmed Panels (20% error) are the real competitor.
- [x] Initialize Git Repository <!-- id: 19 -->
    - [x] Run git init in artifact directory
    - [x] Commit all reports and scripts
    - [x] (Optional) Push to remote if provided
- [ ] Generate Appendix: WGS vs WES TMB Nuance <!-- id: 20 -->
    - [x] Create detailed explanation of the "98% Correlation"
    - [x] Position Panels as the true competitor
    - [x] Commit and Push to Git
    - [x] Rename to "Appendix 1" for consistent numbering
- [x] Generate Appendix 2: MSI Drug & CDx Landscape <!-- id: 21 -->
    - [x] Detail Drugs (Keytruda, Jemperli)
    - [x] Detail Competition (Foundation, Promega)
    - [x] Commit and Push to Git
- [x] Benchmark Caris Reimbursement Strategy <!-- id: 22 -->
    - [x] Research Caris CPT/PLA codes (0244U, 0329U?)
    - [x] Investigate ADLT status and "Market Rate" ruling
    - [x] Generate Appendix 3: Caris $8,000 Roadmap
    - [x] Commit and Push to Git
- [ ] Forecast Sequencing Cost Trends <!-- id: 23 -->
    - [ ] Research NovaSeq X vs Ultima vs Element ($/Gb)
    - [ ] Plot the "Cost Convergence" (WGS vs Panel Labor)
    - [ ] Generate Appendix 4: The COGS Crossover
    - [ ] Commit and Push to Git
- [x] Refine Report 1: HRD Methodologies <!-- id: 7 -->
    - [x] Introduction: Add cancer indications (Ovarian, Breast, Prostate, Pancreatic)
    - [x] Panel: Add toy example of SNP inference and scoring
    - [x] WES: Explain off-target % and CNV -> HRD link
    - [x] Panel: Add TAI and LST toy examples & Myriad scoring details
    - [x] Panel: Add TAI and LST toy examples & Myriad scoring details
    - [x] WES: Add toy example of off-target read binning for CNV -> HRD
    - [x] Panel: Add TAI and LST toy examples & Myriad scoring details
    - [x] WES: Add toy example of off-target read binning for CNV -> HRD
    - [x] Introduction: Explain genomic events caused by HRD (DSBs, Error-Prone Repair)
    - [x] Introduction: Explain genomic events caused by HRD (DSBs, Error-Prone Repair)
    - [x] WGS: Explain probability score calculation (Classifier vs Fraction)
    - [x] Appendix: Detailed explanation of Microhomology Scar formation
